|
Pharmacy -
Pharma Industry - Biotech Industry
|
|
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria. Read more:
|
